Poolbeg Pharma PLC Announces Directorate Change
LONDON, UK / ACCESSWIRE / November 30, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF, 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high …
LONDON, UK / ACCESSWIRE / November 30, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF, 'Poolbeg' or the
'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces a change to its Board
of Directors.
Patrick Ashe, Independent Non-Executive Director, will step down from the Board at the end of November. Patrick played a significant role in guiding the Company through its initial phase of
development. Eddie Gibson, Non-Executive Director will replace Patrick as Chair of the Audit & Risk Committee and Prof Brendan Buckley, Non-Executive Director will become Chair of the
Remuneration Committee.
Cathal Friel, Chairman of Poolbeg Pharma, commented: "We would like to thank Patrick for his contribution since joining at the IPO, where his knowledge and experience of growing
biopharma companies has been of considerable value. Patrick joined the Company as part of its IPO and steps down from the Board at a time when Poolbeg is on an upward trajectory with a robust
pipeline of high value programmes, and at a particularly exciting juncture following the recent appointment of three key former Amryt Pharma plc leadership members to the Poolbeg team with the view
to replicating the success they had with Amryt. With a strong financial position, excellent clinical results achieved and productive partnering discussions ongoing, the Company is well positioned
to generate significant shareholder value."
- Ends -
Enquiries
Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O'Connell, CFO |
+44 (0) 207 183 1499 |
Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker) Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM) |
+44 (0) 207 220 0500 |
Singer Capital Markets (Joint Broker) Phil Davies, Sam Butcher |
+44 (0) 207 496 3000 |
J&E Davy (Joint Broker) Anthony Farrell, Niall Gilchrist |
+353 (0) 1 679 6363 |
Optimum Strategic Communications Nick Bastin, Vici Rabbetts, Elena Bates |
+44 (0) 208 078 4357 poolbeg@optimumcomms.com |
About Poolbeg Pharma
Poolbeg Pharma plc is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need. Its model focusses upon developing its exciting
clinical assets and commercialising approved and marketed drugs to fund the development of its robust pipeline of innovative products, thereby driving significant value creation.
Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt
Pharma plc leadership team, with the intention of repeating Amryt's success and generating near term revenues.
Poolbeg's clinical programmes target large addressable markets across cancer immunotherapies, severe influenza, and metabolic conditions such as obesity with the development of an oral GLP-1R
agonist. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further development. Its AI-led programmes analyse unique data from human
challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal.
For more information, please go to www.poolbegpharma.com or follow us on Twitter and LinkedIn @PoolbegPharma.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Poolbeg Pharma PLC
View source version on accesswire.com:
https://www.accesswire.com/811630/poolbeg-pharma-plc-announces-directo ...
The Poolbeg Pharma Stock at the time of publication of the news with a fall of -1,07 % to 0,093GBP on London stock exchange (29. November 2023, 18:38 Uhr).